Hamburg and Porto, 10/02/2025 | Press Release | Medical Systems Olympus and DigestAID Announce Strategic Partnership to Collaborate on First-in-Field SaMD AI Solutions
Olympus, a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, and DigestAID, a Portuguese startup specializing in GI-specific Software as a Medical Device (SaMD) powered by artificial intelligence (AI), are proud to announce a strategic partnership aimed at transforming the field of digestive healthcare. Together, the two companies plan to introduce innovative SaMD AI-powered solutions in the Hepato-Pancreato-Biliary (HPB) space, further strengthening Olympus’ recent launch of OLYSENSE™ CAD/AI – a suite of cloud-based, AI-powered apps, marking the first step in its intelligent endoscopy ecosystem.
The goal of the intended collaboration is to address long-standing challenges in the diagnostics and treatment of HPB diseases, such as pancreatic cancer, by leveraging advanced AI technology. The partners aim to set a new standard for excellence in the field by combining Olympus’ legacy of innovation and global reach with DigestAID’s pioneering AI technology.
“Olympus is deeply committed to advancing medical technology and improving patient outcomes,” says Miquel-Àngel García, Sr. Vice Pres. and General Manager of Endoscopy Solutions Ecosystem at Olympus. “By joining forces with DigestAID, we are taking a significant step toward improving digestive healthcare, delivering innovative OLYSENSE™ solutions that put patients’ needs first and support clinicians in providing the best care.”
The partnership is intended to focus on developing and deploying the first of their kind interoperable SaMD AI-powered solutions, specifically designed for the HPB field within OLYSENSE™. These innovative solutions aim to integrate seamlessly into existing clinical workflows, equipping healthcare professionals with advanced tools for decision support, predictive insights, and improved diagnostic accuracy. The SaMD seeks to contribute to enhancing patient outcomes in one of the most complex areas of gastroenterology, where accurate and timely diagnoses are critically needed yet often difficult to achieve.
“At DigestAID, we are thrilled to partner with Olympus, a global leader in medical technology,” says Prof. Dr. Miguel Mascarenhas, CEO, Chief Scientific Officer, DigestAID. “Together, we are poised to redefine what’s possible in the HPB space, leveraging AI to create solutions that are innovative and impactful for patients, physicians, and health systems."
